Duke University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Duke University sits in the top decile of US sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count).
Duke University: 1,725 sponsored US clinical trials, 187 recruiting.
Duke University sponsors 1,725 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 1,244 completed. 175 of these trials are in Phase 3-4 (later-stage) and 311 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.
Top-decile sponsor footprint
Duke University ranks in the top decile of sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,244 of 1,444 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,725 total, page 33 of 35
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
NCT00612651
Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features
NCT00610506
Bipolar Disorder in Late Life
NCT00787930
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
NCT00606437
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
NCT00387933
Group Parent Training for Adolescent Eating Disorders
NCT00672906
Relapse Prevention for Suicidal Dually Diagnosed Youths
NCT00589641
Effects of Duloxetine vs. Escitalopram on Heart Rate Variability in Depression
NCT00215228
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
NCT00577629
Does Echocardiographically Guided Ventriculo-Ventricular Optimization Yield a Sustained Improvement in Echocardiographic Parameters in Cardiac Resynchronization Therapy Patients? (DEVISE CRT)
NCT00737490
Neuroimaging Attentional Impairment During Abstinence
NCT00692406
Evaluation of Parenting Interventions to Decrease Family Risk for Child Maltreatment
NCT00586677
Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas
NCT00268359
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
NCT00354913
Preoperative Radiation Therapy for High Risk Prostate Cancer
NCT01041326
Rituximab in the Treatment of Patients With Bullous Pemphigoid
NCT00286325
Evaluation of a Home Visiting Program for First Time Parents
NCT00579449
Comparing Paroxetine and Duloxetine on Cardiovascular Measures
NCT00136383
Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM
NCT00612989
Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas
NCT00612638
Secondary Prevention of Osteoporotic Fractures in Residents of Long-Term Care Facilities
NCT00280943
Early Detection of Breast Cancer Using Tomosynthesis Imaging
NCT00637598
Geodon for the Treatment of Refractory Social Anxiety Disorder
NCT00215150
Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder
NCT00215137
DBT Compared to I/GDC for the Treatment of Opiate Addiction in Emotionally Dysregulated Patients. - 1
NCT00218595
Promoting Postpartum Weight Loss in Overweight Women
NCT00212251
Bortezomib With Melphalan and Prednisone for Multiple Myeloma
NCT00734149
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
NCT00354068
Quit Smoking Program for Lung Cancer Patients' Families (The Family Ties Project)
NCT00345891
Genetics of Peripheral Artery Genomics
NCT00615121
Effects of Resistance and Aerobic Exercise on Cardiovascular Health
NCT00275145
Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence
NCT00215579
Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00362921
Risperidone Augmentation for PTSD
NCT00215241
Virulence Determinants in S Aureus Bacteremia
NCT00319826
Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment
NCT00543296
Quetiapine in Social Anxiety Disorder
NCT00215254
Interventions to Improve Hypertension Control and Reduce Cardiovascular Disease Risk
NCT00201136
Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients
NCT00629447
Weight Management and Coping Skills Training For Patients With Knee Osteoarthritis
NCT00305890
Macronutrient Regulation of Ghrelin and Peptide YY
NCT02464514
Exercise and Dietary Counseling in Improving Physical Activity, Nutrition, and Quality of Life in Older Long-Term Cancer Survivors Who Are Overweight
NCT00303875
Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure
NCT00078286
ENCORE: Exercise and Nutritional Interventions for Cardiovascular Health
NCT00571844
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
NCT00090610
Self System Therapy and Chronic Low Back Pain Trial
NCT00672880
A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel
NCT00131963
Treatment of Obsessive Compulsive Disorder in Children
NCT00074815
Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
NCT00281788
Survival TRaining for ENhancing Total Health (STRENGTH)
NCT00068458
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 136 |
| Phase 2 | 175 |
| Phase 3 | 41 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Duke University pipeline
187 recruiting of 1,725 indexed (11% open); 1,244 completed (72%).
Phase mix: 175 late (III/IV) vs 311 early (I/II) (early-phase heavy).
Top condition: Obesity (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Duke University: open-pipeline peers nationwide
Peers matched on 1,725 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,725 trials (± recruiting share)
- University of California, San Francisco · 1,713 trials · 16% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 11% open enrollment (± trial volume)
- Carnegie Mellon University · 11% recruiting · 37 trials
- CAMC Health System · 11% recruiting · 28 trials
- UConn Health · 11% recruiting · 178 trials
- Hartford Hospital · 11% recruiting · 75 trials
Related
What to do with this Duke University page
1,725 registered trials is a research-attention snapshot, not an endorsement of Duke University or any single study.
- 187 of Duke University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Duke University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Duke University pipeline card: 1,725 registered trials from official public datasets.Report a data error.